Program
fluorophosphate
Also written as “5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice”, “Colgate Cavity protection toothpaste” and “High SLS toothpaste”.
Its studies are mostly in Dentin Sensitivity, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 20 open or running | phase 2since Sep 20, 2012 | Sep 20, 2012 | none ahead |
| Colgate Palmolive | 10 open or running | phase 3since Aug 27, 2025 | Aug 27, 2025 | none ahead |
| Procter and Gamble | 10 open or running | no phasesince Nov 14, 2023 | Nov 14, 2023 | none ahead |
| Solventum | 10 open or running | no phasesince Oct 13, 2020 | Oct 13, 2020 | none ahead |
Also a collaborator on its studies: 3m.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2012First study: phase 2 study in Dentin SensitivityNew to GlaxoSmithKlineGlaxoSmithKline · NCT01691560 · 140 enrolled · United States
- Apr 11, 2013Phase 2 study in Dentinal HypersensitivityGlaxoSmithKline · NCT01831817 · 140 enrolled · United States
- Oct 13, 2020Solventum's first study: no phase study in Oral Mucosal DisorderNew to SolventumSolventum · NCT04601103 · 53 enrolled · United States
- Nov 14, 2023Procter and Gamble's first study: no phase study in CariesNew to Procter and GambleProcter and Gamble · NCT06140758 · 12 enrolled · Australia
- Aug 27, 2025Colgate Palmolive's first study: phase 3 study in Dentin SensitivityNew to Colgate PalmoliveColgate Palmolive · NCT07149376 · 84 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07149376Dentin Sensitivity · United States | 3 | Completed | Colgate Palmolive | Oct 14, 2025 | 84 |
| NCT06140758Caries · Australia | – | Completed | Procter and Gamble | Dec 11, 2023 | 12 |
| NCT04601103Oral Mucosal Disorder · United States | – | Terminated | Solventum | Mar 10, 2020 | 53 |
| NCT01831817Dentinal Hypersensitivity · United States | 2 | Completed | GlaxoSmithKline | May 2013 | 140 |
| NCT01691560Dentin Sensitivity · United States | 2 | Completed | GlaxoSmithKline | Nov 2012 | 140 |
How it is read
Names in the registry
- “5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice”, 2 entries
- “Colgate Cavity protection toothpaste”, 1 entry
- “High SLS toothpaste”, 1 entry
- “Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice”, 1 entry
- “0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice”, 1 entry
Conditions, from the studies’ own filings
- Dentin Sensitivity, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.